Anbio Biotechnology and Oncocyte: A Financial Review

Comparing the manufacturing companies to determine the superior stock

Feb. 9, 2026 at 7:23pm

Got story updates? Submit your updates here. ›

Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) are both manufacturing companies, but which one is the better investment? This article compares the two companies based on factors like valuation, earnings, risk, dividends, institutional ownership, analyst recommendations, and profitability.

Why it matters

This comparison is important for investors looking to make an informed decision between these two healthcare manufacturing companies. The analysis provides insights into the relative strengths and weaknesses of each stock, which can help guide investment decisions.

The details

The article examines key financial metrics for both Anbio Biotechnology and Oncocyte, including net margins, return on equity, and return on assets. It also looks at institutional ownership, analyst ratings, and revenue/earnings comparisons. Anbio Biotechnology is found to outperform Oncocyte on 6 out of 8 factors compared.

  • The financial data analyzed is current as of February 10, 2026.

The players

Anbio Biotechnology

A manufacturing company dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.

Oncocyte Corporation

A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights Anbio Biotechnology's stronger financial performance and market position compared to Oncocyte, making it the more attractive investment option for those looking to gain exposure to the healthcare manufacturing sector.